The largest database of trusted experimental protocols
> Disorders > Neoplastic Process > Cancer of Bladder

Cancer of Bladder

Cancer of the bladder, also known as bladder cancer, is a type of cancer that starts in the cells lining the urinary bladder.
It is one of the most common cancers, and can be treated more effectively when detected early.
Symptoms may include blood in the urine, pain during urination, and frequent urination.
Risk factors include smoking, exposure to certain chemicals, and a history of bladder infections or stones.
Treatment options vary depending on the stage and type of bladder cancer, and may include surgery, radiation therapy, chemotherapy, and immunotherapy.
Researching the latest advances in bladder cancer diagnosis and treatment can help improve patient outcomes and quality of life.

Most cited protocols related to «Cancer of Bladder»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2017
Cancer of Bladder Cell Lines Gene Expression Genome Homo sapiens Malignant Neoplasms RNA-Seq
The main usage of CentiScaPe is to rank the nodes of a network depending on their topological and experimental relevance. The numerical results are saved as node, edge or network attributes in the Cytoscape attributes browser, depending on the kind of parameters, so all the Cytoscape features for managing attributes are supported; after the computation the centralities are treated as normal Cytoscape attributes. CentiScaPe can be used in undirected networks
8 (link), in directed networks and in weighted networks. Centralities for directed networks (see
Supplementary materials: CentralitiesTutorial) are useful in the case of metabolic networks in which the direction describes the interaction between the substrates and reactants and the products of the chemical reactions and also in signal transduction networks, in which the direction depends on the flux of information. Considering the direction in the computation of centralities can lead to different results and interpretations than the undirected version.
As an example, in
Figure 1 we show the computation of the directed and undirected Stress applied to a network of Oncogenes (see
Supplementary materials: Oncogenes.txt and Oncogenes_edge_directions.txt). Results of both the computations are shown and discussed.
The image, obtained using Cytoscape’s graphical tool, represents the different Stress values by using the colour and the size of the nodes. The size describes the value obtained by using the directed Stress: the bigger the node the higher the value; the colour describes the value obtained by using the undirected Stress: red is used for the highest value, blue for the lowest value. For example a large blue node requires particular attention because it is showing a node with a high centrality value if the network is considered as directed but with a very low value if the network is considered as undirected.
By analyzing the Oncogenes network we saw that the large red node, i.e. AKT1, shows how its Stress values are high using both algorithms. It plays a central role in different cell processes like metabolism, proliferation, cell survival, growth and angiogenesis. This role may highlight its high Stress value but, on the other hand, the high values suggest us to deeply investigate its characteristics; it is also involved in two different kind of cancer: breast and colorectal (see
http://www.uniprot.org/uniprot/P31749). This evidence suggest that the node could be involved in cancer related processes but this assertion needs validation from several lab experiments.
Another interesting result is shown by the blue medium sized node RAF1. It shows how, using undirected Stress we obtained a low value, but by using the new algorithm we obtained an interesting Stress value. RAF1 was identified as a proto-oncogene with different and fundamental cellular functions (see
http://www.omim.org/entry/164760). The results could be interpreted by saying that the directed network gives us a better understanding about how the gene, and its product, are involved in the development of cancer and could highlight that the use of the direction enhance our ability in describing a complex biological process.
The opposite situation is found in the third highlighted node, the small green node, RB1 in the right bottom corner. In this case the value computed with undirected Stress is not very high, but the value computed with the directed Stress is very low. RB1 is a gene involved in coding a protein involved in the retinoblastoma and other type of cancer like bladder cancer and osteogenic sarcoma. It was the first tumor suppressor gene found (see
http://www.ncbi.nlm.nih.gov/gene/5925). As already said for RAF1, if the directed analysis is considered more reliable than the undirected one, then RB1 seems to be marginally involved in the Oncogenes network otherwise the undirected network is a better description. As already stated an experimental validation should be carried out in order to improve the results from the topological analysis and to better understand the role of each highlighted node.
All the results shown and described must be considered as a possible direction for further lab experiments. The main goal of this kind of analysis is to give us a comprehensive view that could be useful in describing the role of each node involved in a specific biological process and to drive future insights and investigations.
Second important features of the new version of CentiScaPe is the possibility of computing centralities for weighted networks, that are networks in which the edges are provided with an attribute that can be interpreted as a distance between the two connected nodes.
In the network in
Figure 2 we have a distance (
dist) attribute for each edge. The values are
dist(
A,
B) = 2,
dist(
B,
C) = 3 and
dist(
A,
C) = 7. Since A and C are connected by a single edge, in an unweighted computation, the distance from A to C is equal to one. But if the attributes of the edges are considered as distances, the shortest path between A and C is the one passing through B (= 2 + 3 = 5) since it is shorter, or
lighter, than the one connecting A directly to C (= 7). The computation of weighted shortest paths will result in completely different values from the case wherein the weight is not considered. The user should consider that the weight is used in the sense that close nodes are more important than distant nodes. Therefore depending on the meaning of the attributes, one can use the real value or its reciprocal. For example if the attribute represents the speed of a reaction instead of a distance, the reciprocal should be used. This is because the higher the value of the speed, the nearer the nodes are: an increasing speed determines a decreasing reciprocal and the distance decrease by consequence.
An example of usage of weighted networks centralities analysis, can be found in Holly
et al.9 (link) where an euclidean distance is given to each edge depending on the difference between the phosphorylation level of the proteins connected by that edge.
All the graphical features of the previous version of CentiScaPe, as the plot-by-node, the plot-by-centrality and the boolean-based result panel have been maintained in the new version. A complete guide can be found in Scardoni
et al.8 (link) or in the CentiScaPe userguide available from the website.
Full text: Click here
Publication 2014
AKT1 protein, human angiogen Attention Biological Processes Breast Cancer of Bladder Cell Survival Genes Malignant Neoplasms Metabolic Networks Metabolism Oncogenes Osteosarcoma Phosphorylation Physiology, Cell Proteins Proto-Oncogenes Raf1 protein, human Signal Transduction Staphylococcal Protein A Tumor Suppressor Genes

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2014
Antibodies Cancer of Bladder Cytokeratin KRT20 protein, human Microarray Analysis Phenobarbital Proteins Tissues
344 plasma samples from 200 patients with multiple cancer types were collected along with plasma from 65 healthy controls. Among the patients, 172 individuals, and notably the OV04 samples, were recruited through prospective clinical studies at Addenbrooke’s Hospital, Cambridge, UK, approved by the local research ethics committee (REC reference numbers: 07/Q0106/63; and NRES Committee East of England - Cambridge Central 03/018). Written informed consent was obtained from all patients, and blood samples were collected before and after initiation of treatment with surgery or chemotherapeutic agents. DNA was extracted from 2 mL of plasma using the QIAamp circulating nucleic acid kit (Qiagen) or QIAsymphony (Qiagen) according to the manufacturer’s instructions. In addition, 28 patients were recruited as part of the Copenhagen Prospective Personalized Oncology (CoPPO) program (Ref: PMID: 25046202) at Rigshospitalet, Copenhagen, Denmark, approved by the local research ethics committee. Baseline tumor tissue biopsies were available from all 28 patients, together with re-biopsies collected at relapse from two patients, and matched plasma samples. Brain tumor patients were recruited at Addenbrooke’s Hospital, Cambridge, UK, as part of the BLING study (REC – 15/EE/0094). Bladder cancer patients were recruited at the Netherlands Cancer Institute, Amsterdam, The Netherlands, and approval according to national guidelines was obtained (N13KCM/CFMPB250) (47 ). 65 plasma samples were obtained from healthy control individuals using a similar collection protocol (Seralab). Plasma samples have not been freeze-thawed more than 2 times to reduce artifactual fragmentation of cfDNA. A flowchart of the study is presented in fig. S1.
Publication 2018
Antineoplastic Agents Biopsy BLOOD Brain Neoplasms Cancer of Bladder Cell-Free DNA Cell-Free Nucleic Acids Ethics Committees, Research Freezing Malignant Neoplasms Neoplasms Operative Surgical Procedures Patients Plasma Relapse Tissues
A set of gene signatures positively correlated with the clinical response of an anti-PD-L1 agent (atezolizumab) in BLCA were collected from Mariathasan's study 27 (link). Twelve bladder cancer signatures that are specific to different molecular subtypes were collected from the study performed by the Bladder Cancer Molecular Taxonomy Group 19 (link). We also collected other therapeutic signatures, including oncogenic pathways that could shape a non-inflamed TME, targeted therapy-associated gene signatures, and gene signatures predicting radiotherapy responses (Table S9). The enrichment scores of these signatures were calculated using the GSVA R package 43 (link). Subsequently, it was noted that the mutation statuses of several critical genes, including RB1, ATM, ERBB2, ERCC2, and FANCC, were predictors of the response to neoadjuvant chemotherapy in BLCA 44 (link)-47 (link).
After comparing the differences in the values of the enrichment scores of therapeutic signatures and the mutation statuses of neoadjuvant chemotherapy predictors between Siglec15 groups, we could determine the role of Siglec15 in predicting the response to these therapies. Finally, the BLCA-related drug-target genes were screened using the Drugbank database (Table S10) 48 (link).
Full text: Click here
Publication 2021
atezolizumab Cancer of Bladder CD274 protein, human Drug Delivery Systems ERBB2 protein, human ERCC2 protein, human FANCC protein, human Genes Genes, vif Mutation Neoadjuvant Chemotherapy Oncogenes Radiotherapy

Most recents protocols related to «Cancer of Bladder»

We from the cancer genome atlas (TCGA) database (https://portal.gdc.cancer.gov/) to download the bladder cancer patients (including 414 samples of bladder cancer and 19 adjacent non tumor samples) expression of the spectral data, clinical information, somatic mutation. From Gene Expression Omnibus (GEO) database (https://cancergenome.nih.gov/) download GSE13507 (n = 165) and GSE32894 (n = 224) as an independent verification of the queue. The list of genes involved in glutamine metabolism was obtained from the GenesCards database.
Full text: Click here
Publication 2023
Cancer of Bladder Diploid Cell Genes Genome Glutamine Malignant Neoplasms Metabolism Mutation Neoplasms Patients
Tumor Immune Dysfunction and Exclusion (TIDE) algorithm was used to infer the clinical response of patients to immunotherapy (23 (link)). High TIDE scores were associated with poorer immunotherapy. In addition, we extracted the IMvigor210 dataset, a group of clinical information on the treatment of urothelial carcinoma by anti-PD-L1 monoclonal antibody (atezolizumab) (24 (link)). The relationship between bladder cancer anti-PD-1 and anti-CTLA4 by Immunophenoscores(IPS) scores and GMII. The IPS score is a predictive score for a patient’s response to anti-PD-1 and anti-ctLA-4 treatments (25 (link)). was downloaded from TCIA database (https://tcia.at/home). These results were used to evaluate the predictive value of GMII for immune checkpoint therapy.
Full text: Click here
Publication 2023
atezolizumab Cancer of Bladder Carcinoma, Transitional Cell CD274 protein, human Cell Cycle Checkpoints CTLA4 protein, human Cytotoxic T-Lymphocyte Antigen 4 Immune System Diseases Immunotherapy Monoclonal Antibodies Neoplasms Patients Therapeutics
Bladder cancer samples were clustered by R package “ConsensusClusterPlus” to identify molecular subtypes related to glutamine metabolism. The R package “Survival” was used to perform Kaplan-Meier (KM) survival curves to compare outcomes between the two clusters.
Full text: Click here
Publication 2023
Cancer of Bladder Glutamine Metabolism
Univariate Cox regression analysis was used to screen out the genes associated with overall survival (OS) of bladder cancer, and multivariate Cox regression analysis was used to establish GMII. The Glutamine Metabolism Immunity Index (GMII) was calculated for each patient according to the following formula: Glutamine Metabolism Immunity Index (GMII) = Coef(Gene1) × Expr(Gene1) + Coef(Gene2) × Expr(Gene2) +…… Coef(Genen) × Expr(Genen). Expr(Genen) represents the expression level of a specific gene, and Coef(Genen) represents the coefficient in multivariate Cox analysis. The prognostic value of the features was verified by KM analysis and Receiver Operation Characteristic (ROC) curve, and the prognostic characteristics were verified by GSE13507. Univariate and multivariate Cox analyses were performed to determine whether the characteristics were independent risk factors. According to the clinical characteristic parameters, the correlation and stratification analysis between GMII and clinical characteristics were performed, and the nomogram was constructed to compare the consistency between predicted and actual survival rates by 1-year, 3-year and 5-year calibration maps.
Full text: Click here
Publication 2023
Cancer of Bladder Gene Expression Genes Glutamine Metabolism Microtubule-Associated Proteins Patients Response, Immune
The adhesion and invasion test was performed as described previously (Wang et al., 2018 (link)). The human bladder carcinoma 5,637 cells were cultured in Roswell Park Memorial Institute (RPMI) medium, supplemented with 10% fetal bovine serum (FBS) and 0.1% (w/v) urea, at 37°C and 5% CO2 and inoculated (2 × 105 cells/well) in a 24-well plate. The UTI-ST1 and UTI-ST5 isolates were cultivated in TSB, with or without urea supplementation, to the mid-logarithmic growth phase and washed twice with PBS. Thereafter, the epithelial cells were infected with the UTI isolates at a 1:10 ratio. The adhesion assay was performed by co-incubating bacterial cells and epithelial cells for 2 h at 37°C and 5% CO2. The cells were washed three times with PBS to remove the planktonic bacteria and lysed with 0.1% sodium deoxycholate (Sangon) to release the adhered bacteria. Bacterial CFU was determined by serial dilutions of epithelial cell lysates on TSA plates. For the invasion test, the cells were incubated with bacteria for 4 h, and gentamicin (100 μg/mL) was added to the culture for 30 min to digest the bacteria outside the cells. Thereafter, the bacterial CFU was enumerated to assess the invasion ability.
Full text: Click here
Publication 2023
Bacteria Biological Assay Cancer of Bladder Cells Culture Media Deoxycholic Acid, Monosodium Salt Epithelial Cells Fetal Bovine Serum Gentamicin Homo sapiens Plankton Technique, Dilution Urea

Top products related to «Cancer of Bladder»

Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
Sourced in United States, China, Germany, United Kingdom, Japan, France, Canada, Australia, Italy, Switzerland, Belgium, New Zealand, Spain, Israel, Sweden, Denmark, Macao, Brazil, Ireland, India, Austria, Netherlands, Holy See (Vatican City State), Poland, Norway, Cameroon, Hong Kong, Morocco, Singapore, Thailand, Argentina, Taiwan, Province of China, Palestine, State of, Finland, Colombia, United Arab Emirates
RPMI 1640 medium is a commonly used cell culture medium developed at Roswell Park Memorial Institute. It is a balanced salt solution that provides essential nutrients, vitamins, and amino acids to support the growth and maintenance of a variety of cell types in vitro.
Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica
DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.
Sourced in United States, China, United Kingdom, Germany, France, Canada, Japan, Australia, Italy, Switzerland, Belgium, New Zealand, Austria, Netherlands, Israel, Sweden, Denmark, India, Ireland, Spain, Brazil, Norway, Argentina, Macao, Poland, Holy See (Vatican City State), Mexico, Hong Kong, Portugal, Cameroon
RPMI 1640 is a common cell culture medium used for the in vitro cultivation of a variety of cells, including human and animal cells. It provides a balanced salt solution and a source of essential nutrients and growth factors to support cell growth and proliferation.
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.
Sourced in United States, Germany, China
The UMUC3 is a laboratory equipment item offered by American Type Culture Collection. It is designed to facilitate the culturing and growth of microbial samples. The core function of the UMUC3 is to provide a controlled environment for the cultivation of various microorganisms.
Sourced in United States, China, Germany, United Kingdom, Canada, Japan, France, Italy, Switzerland, Australia, Spain, Belgium, Denmark, Singapore, India, Netherlands, Sweden, New Zealand, Portugal, Poland, Israel, Lithuania, Hong Kong, Argentina, Ireland, Austria, Czechia, Cameroon, Taiwan, Province of China, Morocco
Lipofectamine 2000 is a cationic lipid-based transfection reagent designed for efficient and reliable delivery of nucleic acids, such as plasmid DNA and small interfering RNA (siRNA), into a wide range of eukaryotic cell types. It facilitates the formation of complexes between the nucleic acid and the lipid components, which can then be introduced into cells to enable gene expression or gene silencing studies.
Sourced in United States, China, Japan, Germany, United Kingdom, Canada, France, Italy, Australia, Spain, Switzerland, Netherlands, Belgium, Lithuania, Denmark, Singapore, New Zealand, India, Brazil, Argentina, Sweden, Norway, Austria, Poland, Finland, Israel, Hong Kong, Cameroon, Sao Tome and Principe, Macao, Taiwan, Province of China, Thailand
TRIzol reagent is a monophasic solution of phenol, guanidine isothiocyanate, and other proprietary components designed for the isolation of total RNA, DNA, and proteins from a variety of biological samples. The reagent maintains the integrity of the RNA while disrupting cells and dissolving cell components.
Sourced in United States, China
The SV-HUC-1 is a type of laboratory equipment designed for the culturing and maintenance of human urinary bladder cells. It provides a controlled environment for the growth and propagation of these specific cell lines.
Sourced in United States, Germany
The HT1376 is a laboratory equipment designed for cell culture and biological research applications. It provides a controlled environment for the growth and maintenance of cell cultures. The HT1376 is capable of precisely regulating temperature, humidity, and atmospheric gas composition to support the specific needs of various cell types.

More about "Cancer of Bladder"

Bladder cancer, also known as urothelial carcinoma, is a type of cancer that originates in the urothelial cells lining the urinary bladder.
It is one of the most prevalent cancers, with early detection being crucial for effective treatment.
Symptoms may include hematuria (blood in the urine), dysuria (painful urination), and increased urinary frequency.
Risk factors for bladder cancer include smoking, exposure to certain chemicals (such as those found in the rubber, dye, and aluminum industries), and a history of bladder infections or stones.
Treatment options for bladder cancer vary depending on the stage and type of the disease.
These may include surgical interventions (e.g., transurethral resection of bladder tumor, partial or radical cystectomy), radiation therapy, chemotherapy (e.g., intravesical instillation of BCG or chemotherapeutic agents like mitomycin C, gemcitabine, or cisplatin), and immunotherapy (e.g., intravesical instillation of Bacillus Calmette-Guérin (BCG)).
In the laboratory, bladder cancer research often utilizes cell lines such as UMUC3, HT1376, and SV-HUC-1 to study the disease's biology and test potential therapies.
These cell lines are typically cultured in media like RPMI 1640 and DMEM, supplemented with fetal bovine serum (FBS) and penicillin/streptomycin antibiotics.
Techniques like Lipofectamine 2000 transfection and TRIzol reagent extraction are commonly employed to manipulate and analyze these cell models.
Staying up-to-date with the latest advancements in bladder cancer diagnosis and treatment, as well as leveraging AI-driven research optimization tools like PubCompare.ai, can help researchers and clinicians improve patient outcomes and quality of life.